Recursion Pharmaceuticals (RXRX) Short-term Investments (2020 - 2026)

Recursion Pharmaceuticals' Short-term Investments history runs 7 years deep, the most recent figure standing at $5.5 million for Q1 2026.

• Quarterly Short-term Investments rose 79.22% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (up 79.22% YoY) and the FY2025 annual result came in at $4.6 million, up 50.87% from the prior year.
• Short-term Investments was $5.5 million for Q1 2026 at Recursion Pharmaceuticals, up from $4.6 million in the prior quarter.
• Across five years, Short-term Investments topped out at $5.5 million in Q1 2026 and bottomed at $1.3 million in Q4 2022.
• A 5-year average of $2.7 million and a median of $3.0 million in 2024 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2022 — Short-term Investments tumbled 99.45% — and 2023, when it surged 152.42%.
• Recursion Pharmaceuticals' Short-term Investments stood at $1.3 million in 2022, then soared by 152.42% to $3.2 million in 2023, then declined by 5.76% to $3.0 million in 2024, then jumped by 50.87% to $4.6 million in 2025, then grew by 19.96% to $5.5 million in 2026.
• Business Quant data shows RXRX's Short-term Investments at $5.5 million in Q1 2026, $4.6 million in Q4 2025, and $3.1 million in Q3 2025.